

Amendment to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

Claims 1 – 10 (canceled).

Claim 11 (previously presented): A method comprising administering atorvastatin or a pharmaceutically acceptable salt thereof in an amount effective to cause an aggressive lowering of LDL cholesterol by about fifty percent or more from baseline for the prevention or delay of catheter-based revascularization in patients suffering from coronary artery disease in need of such treatment wherein said patients have undergone prior angiography.

Claim 12 (previously presented): The method according to Claim 11, wherein the amount of atorvastatin administered is from about 50 mg/day to about 150 mg/day.

Claim 13 (previously presented): The method according to Claim 12 wherein atorvastatin is administered at a dose of about 80 mg/day.

Claim 14 (previously presented): The method according to Claim 1 wherein atorvastatin is administered as the sole active ingredient.

Claim 15 (previously presented): The method according to Claim 5 wherein atorvastatin is administered as the sole active ingredient.

Claim 16 (previously presented): The method according to Claim 11 wherein atorvastatin is administered as the sole active ingredient.

Claim 17 (previously presented): The method according to Claim 13 wherein atorvastatin is administered as the sole active ingredient.

Claims 18 – 22 (canceled).